Bio Products Laboratory announced that the FDA has approved Gammaplex 10% (immune globulin intravenous [human], 10% liquid) for the treatment...
Octapharma USA announced that the FDA has approved Octagam 10% (immunogGlobulin Intravenous liquid) for the treatment of adults with Chronic...
The aim of these recommendations is to set forth an individualized approach to the management of early postmenopausal women (i.e., within the first 10 years after natural menopause) covering all aspects of lifestyle and therapeutic management, with or without menopause hormone therapy (MHT).